BullishAgent BullishAgent SEC Filings Earnings Calendar Analyst Ratings IPOs Insiders Institutional Funds Screener
Sign in Register

CELUW

Celularity Inc. NASDAQ
Healthcare ·Biotechnology ·US · celularity.com
$0.01
Mkt Cap $248,346
52w Low $0.01 10.4% of range 52w High $0.03
50d MA $0.01 200d MA $0.03
P/E (TTM) 0.0x
EV/EBITDA -1.5x
P/B
Debt/Equity -1.8x
ROE 322.8%
P/FCF -2.1x
RSI (14)
ATR (14)
Beta 0.70
50d MA $0.01
200d MA $0.03
Avg Volume 13.0K
About
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical tri…
Recent Earnings
Date Time Est Rptd Surp Base Gap% D1% D2% D3% D4% D5% 1M% Guide ▲★
Mar 30, 2026 AMC -1.50 -0.85 +43.3% 0.01 -12.6% +13.8% -12.6% -11.5% -10.3% -9.2% +3.4%
Nov 14, 2025 AMC -1.50 -0.88 +41.6% 0.02 +11.8% +11.8% +42.2% +32.7% -12.6% +37.2% +7.0%
Aug 29, 2025 AMC -1.02 0.06 +0.0% +0.0% -31.7% -8.3% -8.7% -16.8% -41.5%
Jun 30, 2023 AMC -0.00 0.06 +7.3% +6.3% +22.2% -11.0% -6.3% -12.7% -15.0%
Mar 31, 2023 AMC -0.00 0.06 -1.7% +4.2% +8.3% +16.7% +16.7% +16.7% +3.3%
Dec 31, 2022 AMC
Recent Analyst Ratings
Date Firm Action Grade Target Base Open Gap% D1% D2% D3% D4% D5%
Jan 29 HC Wainwright & Co. Maintains Buy → Buy
Jan 29 Morgan Stanley Downgrade Equal Weight → Underweight
Dec 21 Oppenheimer Downgrade Outperform → Perform $0.12 $0.10 -16.7% +2.1% -32.8% -25.0% -25.0% -39.0%
Sep 11 Morgan Stanley Maintains Equal Weight → Equal Weight
Aug 22 Truist Maintains Hold → Hold $0.40 $0.43 +7.4% +7.4% -14.6% +0.0% -15.0% -13.8%
Apr 5 Truist Downgrade Buy → Hold $1.29 $1.29 +0.0% +3.9% +0.8% -0.8% -1.6% +6.2%
Data updated apr 28, 2026 4:49am · Source: massive.com